@article{5228bb8e5c47467a96e54a0b8ad101c9,
title = "Potential impact of family history–based screening guidelines on the detection of early-onset colorectal cancer",
abstract = "Background: Initiating screening at an earlier age based on cancer family history is one of the primary recommended strategies for the prevention and detection of early-onset colorectal cancer (EOCRC), but data supporting the effectiveness of this approach are limited. The authors assessed the performance of family history–based guidelines for identifying individuals with EOCRC. Methods: The authors conducted a population-based, case-control study of individuals aged 40 to 49 years with (2473 individuals) and without (772 individuals) incident CRC in the Colon Cancer Family Registry from 1998 through 2007. They estimated the sensitivity and specificity of family history–based criteria jointly recommended by the American Cancer Society, the US Multi-Society Task Force on CRC, and the American College of Radiology in 2008 for early screening, and the age at which each participant could have been recommended screening initiation if these criteria had been applied. Results: Family history–based early screening criteria were met by approximately 25% of cases (614 of 2473 cases) and 10% of controls (74 of 772 controls), with a sensitivity of 25% and a specificity of 90% for identifying EOCRC cases aged 40 to 49 years. Among 614 individuals meeting early screening criteria, 98.4% could have been recommended screening initiation at an age younger than the observed age of diagnosis. Conclusions: Of CRC cases aged 40 to 49 years, 1 in 4 met family history–based early screening criteria, and nearly all cases who met these criteria could have had CRC diagnosed earlier (or possibly even prevented) if earlier screening had been implemented as per family history–based guidelines. Additional strategies are needed to improve the detection and prevention of EOCRC for individuals not meeting family history criteria for early screening.",
keywords = "case-control study, family history, guidelines, sensitivity, specificity, young-onset colorectal cancer",
author = "Samir Gupta and Balambal Bharti and Ahnen, {Dennis J.} and Buchanan, {Daniel D.} and Cheng, {Iona C.} and Michelle Cotterchio and Figueiredo, {Jane C.} and Gallinger, {Steven J.} and Haile, {Robert W.} and Jenkins, {Mark A.} and Lindor, {Noralane M.} and Macrae, {Finlay A.} and {Le Marchand}, Lo{\"i}c and Newcomb, {Polly A.} and Thibodeau, {Stephen N.} and Win, {Aung Ko} and Martinez, {Maria Elena}",
note = "Funding Information: Supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award NCI/NIH 5R37CA222866 (to Samir Gupta) and VA HSRD 5 I01 HX001574-04 (to Samir Gupta). Additional funding to the Colon Cancer Family Registry (CCFR) was provided under award U01CA167551 and through cooperative agreements with the following CCFR centers: Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24 CA097735), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (U01/U24 CA074794), University of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806 and R01 CA104132), and University of Southern California Consortium Colorectal Cancer Family Registry (U01/U24 CA074799). The content of this article does not necessarily reflect the views or policies of the NCI or any of the collaborating centers in the CCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR. Funding Information: Samir Gupta received a grant from the National Cancer Institute for work performed as part of the current study; is chair of the National Comprehensive Cancer Network colorectal high risk/genetics guideline panel and a member of the US Multi‐Society Task Force on colorectal cancer guidelines, both of which were referenced in the current study; and serves on a research trial steering committee for Guardant Health and the scientific advisory board for Freenome. Dennis J. Ahnen has acted as a paid member of the Speakers' Bureau for Ambry Genetics and serves as a scientific advisor for Cancer Prevention Pharmaceuticals for work performed outside of the current study. Michelle Cotterchio received a research grant from the National Institutes of Health for work performed as part of the current study. The other authors made no disclosures. Funding Information: Supported by the National Cancer Institute (NCI) of the National Institutes of Health (NIH) under award NCI/NIH 5R37CA222866 (to Samir Gupta) and VA HSRD 5 I01 HX001574‐04 (to Samir Gupta). Additional funding to the Colon Cancer Family Registry (CCFR) was provided under award U01CA167551 and through cooperative agreements with the following CCFR centers: Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24 CA097735), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (U01/U24 CA074794), University of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806 and R01 CA104132), and University of Southern California Consortium Colorectal Cancer Family Registry (U01/U24 CA074799). The content of this article does not necessarily reflect the views or policies of the NCI or any of the collaborating centers in the CCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CCFR. Publisher Copyright: {\textcopyright} 2020 American Cancer Society",
year = "2020",
month = jul,
day = "1",
doi = "10.1002/cncr.32851",
language = "English (US)",
volume = "126",
pages = "3013--3020",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "13",
}